Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Real-World Data Linkage Research Platform

3 juni 2026 bijgewerkt door: Kong Yuanyuan, Beijing Friendship Hospital

This study aims to address the lack of intelligent governance tools in clinical data management to promote efficient governance and secure sharing of real-world health data. To achieve this, a self-adaptive, automated governance intelligent agent will be developed based on a High-Order Programming (HOP) architecture, integrating Large Language Models (LLMs) and deep learning techniques. The agent will continuously monitor and correct data quality issues in real time, improving data accuracy and usability.

In parallel, the project will establish a trusted data-sharing framework by integrating AI Confidential Computing (AICC) with Trusted Data Matrix (TDM) technologies. This framework will enable secure, real-time cross-institutional data exchange and collaborative computation while protecting sensitive information.

Overall, the study aims to transform fragmented clinical data into high-quality, standardized, and securely accessible resources, thereby facilitating the circulation of data value and advancing collaborative medical research.

Studie Overzicht

Gedetailleerde beschrijving

This multicenter, observational cohort study aims to integrate longitudinal health data from China, including routine health examinations, electronic medical records, and disease registries. The platform is designed to address key data challenges in the medical domain, particularly in chronic diseases and suboptimal health status. It is driven by two primary objectives:

  1. Intelligent and automated data governance To ensure high data quality, the platform will engineer a self-adaptive, automated governance intelligent agent. Integrating Large Language Models (LLMs) and High-Order Programming (HOP), this agent actively monitors and corrects real-world data issues, such as missing values, redundancies, and formatting inconsistencies. Through deep learning, the agent continuously optimizes its governance rules to adapt to complex medical data environments.
  2. Trusted and secure data sharing To facilitate multicenter collaborative research, the study will establish a secure and trusted data-sharing framework. By integrating AI confidential computation (AICC) with Trusted Data Matrix (TDM) technologies, the platform provides hardware-level security guarantees. This ensures that real-time, cross-institutional data exchange and collaborative computation without exposing sensitive patient information.

Overall Objective The platform aims to transform heterogeneous clinical data into standardized, high-quality, and securely accessible resources, thereby enabling efficient data utilization and promoting the value circulation of medical data for real-world evidence research.

Studietype

Observationeel

Inschrijving (Geschat)

300000

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Yuanyuan Kong, PhD
  • Telefoonnummer: +86 1063139362 +86 15810026760
  • E-mail: kongyy@ccmu.edu.cn

Studie Contact Back-up

Studie Locaties

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100050
        • Beijing Friendship Hospital, Capital Medical University.No. 95, Yongan Road, Xicheng District, Beijing, 100050, China

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

This study establishes a multicenter, observational real-world data platform integrating longitudinal health data from multiple sources across China, including routine health examinations, electronic medical records, and disease registries. The platform is designed to support population-level research without restriction to specific diseases or conditions, enabling inclusive and continuous assessment of health status, disease risk, progression, and outcomes in real-world settings.

All available individuals with usable health-related data are eligible for inclusion, with minimal restrictions to maximize data coverage and representativeness. Both retrospective and prospective data will be incorporated and linked at the individual level using standardized protocols within a secure data governance and privacy protection framework.

Beschrijving

Inclusion Criteria:

  • Participants will be eligible for inclusion if they meet all of the following criteria:

    1. Availability of any health-related data generated from routine clinical care, health examinations, or disease surveillance systems, regardless of disease type or health status.
    2. Presence of at least one type of usable data, including but not limited to diagnostic information (structured or unstructured), laboratory results, imaging data, or basic demographic information.
    3. Records contain sufficient information (appropriately anonymized) to allow data organization and, where feasible, linkage at the individual level across time points or data sources.

Exclusion Criteria:

  • Participants or records meeting any of the following criteria will be excluded:

    1. Records lacking minimal essential information required to distinguish individual records or support basic analysis (e.g., completely missing identifiers or time information).
    2. Records confirmed to be invalid, including system-generated test data, corrupted entries, or records that do not represent real clinical or health-related events.
    3. Exact duplicate records that cannot be resolved through standard data processing (only one record will be retained when duplicates are identifiable).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Data-Link Cohort
The study cohort is derived from a multicenter, population-based real-world data platform that integrates longitudinal data from electronic medical records, disease registries, and routine health examinations across multiple institutions. The platform is designed to support broad, disease-agnostic research and enable dynamic evaluation of health status, disease risk, and outcomes in real-world settings.
This is an observational study. No intervention will be applied.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Accuracy Rate of Automated Data Governance
Tijdsspanne: 2026.5.30 to 2028.12.31
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in improving data accuracy will be evaluated by measuring the proportion of data values that correctly match the gold-standard reference after automated data governance. The accuracy rate will be calculated as the percentage of correctly recorded or corrected data elements among all evaluated data elements. Values range from 0% to 100%, with higher values indicating better data accuracy.
2026.5.30 to 2028.12.31
Completeness Rate of Automated Data Governance
Tijdsspanne: 2026.5.30 to 2028.12.31
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in improving data completeness will be evaluated by measuring the proportion of required data fields that are complete after automated data governance. The completeness rate will be calculated as the percentage of non-missing required data elements among all required data elements. Values range from 0% to 100%, with higher values indicating better data completeness.
2026.5.30 to 2028.12.31

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Correction Accuracy of Automated Data Governance
Tijdsspanne: 2026.5.30 to 2028.12.31
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in resolving identified data quality issues will be evaluated by measuring correction accuracy. Correction accuracy will be calculated as the percentage of identified data quality issues (e.g., missing values, format inconsistencies, and logical conflicts) that are correctly resolved after automated data governance, compared with the gold-standard reference dataset. Values range from 0% to 100%, with higher values indicating better correction performance.
2026.5.30 to 2028.12.31
Data Standardization Rate of Automated Data Governance
Tijdsspanne: 2026.5.30 to 2028.12.31
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in standardizing data will be evaluated by measuring the proportion of data elements that conform to predefined data standards, terminologies, and formatting rules after automated data governance. The data standardization rate will be calculated as the percentage of evaluated data elements that meet standardized data specifications among all assessed data elements. Values range from 0% to 100%, with higher values indicating better data standardization.
2026.5.30 to 2028.12.31
Cross-institutional Data Usability of Automated Data Governance
Tijdsspanne: 2026.5.30 to 2028.12.31
Using datasets derived from participating institutions, the effectiveness of the intelligent agent in improving cross-institutional data usability will be evaluated by measuring the proportion of governed datasets that can be successfully integrated, interpreted, and used across different institutions according to predefined interoperability and usability criteria after automated data governance. Cross-institutional data usability will be calculated as the percentage of datasets meeting prespecified usability criteria among all evaluated datasets. Values range from 0% to 100%, with higher values indicating better cross-institutional usability.
2026.5.30 to 2028.12.31

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Yuanyuan Kong, Beijing Friendship Hospital

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

30 mei 2026

Primaire voltooiing (Geschat)

31 december 2028

Studie voltooiing (Geschat)

31 december 2030

Studieregistratiedata

Eerst ingediend

20 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

3 juni 2026

Eerst geplaatst (Werkelijk)

9 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

3 juni 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren